cc-5013
Metastatic Kidney Medullary Carcinoma
M.D. Anderson Cancer CenterPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Metastatic Kidney Medullary Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Inno-206 M.D. Anderson Cancer Center | Phase 2 | CCC |
mln9708 M.D. Anderson Cancer Center | Phase 2 | CCC |
Pembrolizumab Giuseppe Procopio | Phase 2 | CCC |
DEXAMETHASONE M.D. Anderson Cancer Center | Phase 2 | CCC |
Cyclophosphamide M.D. Anderson Cancer Center | Phase 2 | CCC |
Epirubicin M.D. Anderson Cancer Center | Phase 2 | CCC |
Same molecule, other indications
cc-5013 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →